Endocannabinoid Deficiency Theory
In our previous post, we touched on the endocannabinoid system and how this neurological network works within our bodies to maintain systematic homeostasis. Cannabinoids work with CB1 and CB2 receptors to aid in regulatory functions concerning inflammation, immune response, metabolic performance, as well as a host of other operations within the human body. As an expansion on this topic, it is important to discuss endocannabinoid deficiency theory in relation to the many health claims that are tied to cannabinoids and CBD use. As always, first and foremost, any health related decisions should be discussed with a doctor, especially if you are being treated with medication for any condition. There are certain enzymes within the body that render CBD incompatible for use with certain prescription medication.
We here at Revexia do the digging in order to have the knowledge to offer insight into questions you might have regarding if CBD is right for you.
What is clinical endocannabinoid deficiency?
Clinical endocannabinoid deficiency theory is a new horizon in CBD research; it might hold the key to unanswered conditions such as autoimmune disease, fibromyalgia, and other widespread systematic disorders.
This theory was first introduced in 2001 and highlights the neurological function, or dysfunction of the cannabinoid receptors in the body. The belief is that a lack of endocannabinoid production in the body, or ineffective receptors contribute to an imbalance in the body. This leads to an ineffective or over reactive immune system, or hyperactive inflammatory response. Current studies examine the function of endocannabinoids in patients with conditions like irritable bowel syndrome and migraines, as well as psychological conditions like anxiety and post-traumatic stress disorder. From the limited studies that have been conducted, there is an indication that introduction of a CBD regimen could be helpful in these cases.
Why does this matter?
Because research has seen so many different health conditions responding favorably to CBD treatment, medical professionals hypothesize that endocannabinoid deficiency could be the underlying commonality. Cannabinoids are unique in that they do not treat diseases themselves; rather they activate regulatory systems in the body that might not be working the way they should. The hypothesis is that these hard to treat diseases could all be a product of some kind of deficiency, merely manifesting itself in different ways.
Neurotransmitter deficiencies are cited as the cause for many diseases such as Parkinson’s, Alzheimer’s, and depression. Science has identified the presence of a chemical imbalance in these conditions, marked by a either a lack of chemicals or hormones, or a failure of the receptors that utilize them.
Because the endocannabinoid system works in areas like inflammation, immunity, and cell function, it naturally fits the attributes of autoimmune diseases. Endocannabinoid deficiency could have the ability to explain the pathology behind functional disorders. In a study published in 2004 by Neuroendocrinology Letters, endocannabinoid deficiency theory is considered provable, but requires extensive research.
It is already apparent through the few studies that have been done so far that cannabinoids have some kind of impact on many systems in the body. Many have claimed overwhelmingly positive results from CBD use. The discovery of the endocannabinoid system itself was impactful in understanding systematic function. However, what remains to be researched and uncovered is if endocannabinoid deficiency theory can be substantiated as an explanation for so many unexplained disorders.
It is clear however, that this is an avenue that should be explored further, for the sake of so many who face diseases that cannot be solved by current traditional medicine.
If you are interested in trying CBD or just want more information about the endocannabinoid system, feel free to call Revexia anytime at (970) 449-1603, or stop by our storefront at 1724 Topaz Dr. in Loveland.